Please try another search
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer, other solid tumors, other fibrotic disease, and scar reduction which is in clinical trial. It also develops AMP886, which is in preclinical trial for treating solid tumors. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Name | Age | Since | Title |
---|---|---|---|
Mark Devlin | - | 2018 | Member of Scientific Advisory Board |
Robert Peach | 68 | 2015 | Independent Non-Executive Director |
Paul Timpson | - | 2020 | Member of Scientific Advisory Board |
Jane Catherine Bell | - | 2021 | Independent Non-Executive Director |
Margaret Frame | - | - | Member of Scientific Advisory Board |
Jason Lickliter | - | - | Member of Clinical Advisory Board |
Warwick Tong | 73 | 2018 | Independent Non-Executive Chairman |
Christopher J. Burns | 60 | 2018 | CEO, MD & Director |
Jose L. Iglesias | 67 | - | Member of Clinical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review